Apridonidze, T., Essah, P.A., Iuorno, M.J. and Nest-ler, J.E. 20005. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. – J. Clin. Endocrinol. Metabol. 90: 1929-1935.
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Ka-ndarakis, E., Escobar-Morreale, H.F. and Futterweit, W. 2006. Positions statement: criteria for defining polycystic ovary syndrome as a predomin-antly hyperandrogenic syndrome: an Androgen Excess Society guideline. – J. Clin. Endocrinol. Metabol. 91: 4237-4245.
Azziz, R., Woods, K.S., Reyna, R., Key, T.J., Knochenhauer, E.S. and Yildiz, B.O. 2004. The preva‌lence and features of the polycystic ovary synd-rome in an unselected population. – J. Clin. Endo-crinol. Metabol. 89: 2745-2749.
Boulman, N., Levy, Y., Leiba, R., Shachar, S., Linn, R. and Zinder, O. 2004. Increased C - reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. – J. Clin. Endocrinol. Metab. 89: 2160-2165.
Brzozowska, M.M., Ostapowicz, G. and Weltman, M.D. 2009. An association between non-al‌coholic fa-tty liver disease and polycystic ovarian syndrome. – J. Gastroenterol. Hepatol. 24: 243-247.
Cai, D., Yuan, M., Frantz, D.F., Melendez, P.A., Ha-nsen, L., Lee, J. and Shoelson, S.E. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. – Nat. Med. 11: 183-190.
Carmina, E., Napoli, N., Longo, R.A., Rini, G.B. and Lobo, R.A. 2006. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of the criteria for the diagnosis of PCOS. – Eur. J. Endocrinol. 154: 141-145.
Chan, D.F., Li, A.M., Chu, W.C., Chan, M.H., Wong, E.M., Liu, E.K., Chan, I.H., Yin, J., Lam, C.W., Fok, T.F. and Nelson, E.A. 2004. Hepatic ste‌atosis in obese Chinese children. – Int. J. Obes. Relat. Metab. Dis‌ord. 28: 1257-1263.
Chang, R.J., Nakamura, R.M. and Judd, H.L. 1983. Insulin resistance in nonobese patients with polycystic ovarian disease. – J. Clin. Endocrinol. Metab. 57: 356-359.
Dokras, A., Bochner, M., Hollinrake, E., Marklam, S., VanVoorhis, B. and Jagasia, D.H. 2005. Screening women with polycystic ovary syndrome for metabolic syndrome. – Obstet. Gynecol. 106: 131-137.
Edmison, J. and McCullough, A.J. 2007. Pathogenesis of non-alcoholic steatohepatitis: human data. – Clin. Liver Dis. 11: 75-104
Franks, S. 1995. Polycystic ovary syndrome. – N. Engl. J. Med. 333: 853-861.
Haukeland, J.W., Damås, J.K., Konopski, Z., Løberg, E.M., Haa‌land, T., Goverud, I., Torjesen, P.A., Bi-rkeland, K., Bjøro, K. and Auk‌rust, P. 2006. Syst-emic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. – J. He-patol. 44: 1167-1174.
James, A. and Duke. 2008. Phytochemical Databases, Beltsvilla Argriculture Research Center. – Green Fa-rmacy Garden.
Janbakhsh, A., Mansouri, F., Vaziri, S., Sayad, B., Afsharian, M. and Rahimi, M. 2013. Effect of sele-nium on immune response against hepatitis B vaccine with accelerated method in insulin-dependent diabetes mellitus patients. – Caspian J. Intern Med. 4: 603-606.
Klover, P.J., Clementi, A.H. and Mooney, R.A. 2005. Interleukin-6 deple‌tion selectively improves hepatic insulin action in obesity. – Endocrinology. 146: 3417-3427.
Legro, R.S., Kunselman, A.R., Dodson, W.C. and Du-naif, A. 1999. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. – J. Clin. Endocrinol. Metabol. 84: 165-169.
Miller, A.M. and McInnes, I.B. 2011. Cytokines as therapeutic targets to reduce cardiovascular risk in ch-ronic inflammation. – Curr. Pharm. Des. 17: 1-8.
Monfared, M., Kamkar, A., Ghaffari-Khaligh, S., Je-belli- Javan, A., Asadi, F. and Akhundzadeh-Basti, A. 2011. Antioxidative effects of Iranian Urtica dioica L. extracts on the oxidation of sunflower oil. – J. Med. Plants Res. 5: 4438-4445.
Onal, S., Timur, S., Okutucu, B. and Zihnioğlu, F. 2005. Inhibition of alpha-glucosidase by aqueous ex-tracts of some potent antidiabetic medicinal herbs. – Prep. Biochem. Biotechnol. 35: 29-36.
Parvizpur, A., Ahamadiani, A. and Kamalinejad, M. 2001. Probable role of purinergic system in antinocic-eptive effects of Trigonella foenumraecum leaves extract. – 14th International Congress of Geographic Medicine and 15th Iranian Congress of Physiology and Pharmacology. Shiraz- Iran. 5- 8: 346.
Sathyapalan, T. and A.S. 2010. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. – Mediators of Inflammation. doi: 10.1155/2010/758656.
Srikanthan, P., Korenman, S. and Davis, S. 2006. Po-lyciystic ovarian syndrome: the next cardio‌vascular dilemma in women? – Endocrinol. Metab. Clin. North Am. 35: 611-631.
Teucher, T., Obertreis, B., Ruttkowski, T. and Schm-itz, H. 1996. Cytokine secretion in whole blood of healthy subjects following oral administration of Urtica dioica L. plant extract. – Arzneimittelfors-ch-ung. 46: 906-910.
Tilg, H. and Diehl, A.M. 2000. Cytokines in alcoholic and nonalcoholic steatohepatitis. – N. Engl. J. Med. 343: 1467-1476.
Tracey, K.J. and Cerami, A. 1993. Tumor necrosis factor, other cytokines and disease. – Annu. Rev. Cell. Biol. 9: 317-343.
Verma, S., Devaraj, S. and Jialal, I. 2006. C Reactive protein promotes atherothrombosis. – Circulation. 113: 2135–2150.
Villuendas, G., San Millan, J.L., Sancho, J. and Escobar-Morreale, H.F. 2002. The 2597 G ! A and 2174 G ! C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. – J. Clin. Endocrinol. Metabol. 87: 1134–1141.
Walters, K.A., Allan, C.M. and Handelsman, D.J. 2012. Rodent models for human polycystic ovary syndrome. – Biol. Reprod. 86: 1-12.
Wieckowska, A., Papouchado, B.G., Li, Z., Lopez, R., Zein, N.N. and Feldstein, A.E. 2008. Increased hepa-tic and circulating interleu‌kin-6 levels in human nonalcoholic steatohepatitis. – Am. J. Gastroenterol. 103: 1372-1379.
Yamaguchi, K., Itoh, Y., Yokomizo, C., Nishimura, T., Niimi, T., Fujii, H., Okanoue, T. and Yosh-ikaw-a, T. 2010. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver in‌jury in methionine choline-deficient diet-fed mice. – Lab. Invest. 90: 1169-1178.
Yudkin, J.S., Kumari, M., Humphries, S.E. and Mohamed-Ali, V. 2000. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? –Atherosclerosis. 148: 209-214.